Literature DB >> 29775158

microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer.

Ahmed Hussein Zedan1,2,3, Torben Frøstrup Hansen2,3, Jannie Assenholt4, Mindaugas Pleckaitis5, Jonna Skov Madsen3,4, Palle Jörn Sloth Osther1,3.   

Abstract

Prostate cancer is the most common cancer among men in the western world. Clinical practice is continuously challenged by the pitfalls of the available diagnostic tools. microRNAs may represent promising biomarkers in many types of human cancers, including prostate cancer. The aim of this study was to investigate microRNA expression in tumour tissue and matched plasma in a cohort of patients with primary metastatic prostate cancer. The relative expression of 12 microRNAs was assessed in diagnostic needle biopsies from the prostate and matched plasma samples in two prospective cohorts (screening cohorts) comprising 21 patients with metastatic prostate cancer and 25 control patients. An independent validation cohort of plasma samples was collected prospectively from 149 newly diagnosed patients with local/locally advanced prostate cancer. Analyses were performed using real-time polymerase chain reaction. miRNA-93 showed a significant negative correlation between expression in tumour tissue and plasma in patients with metastatic prostate cancer. Furthermore, the plasma level of miRNA-93 significantly decreased after treatment in patients with local/locally advanced prostate cancer compared to baseline plasma level. The expression of six microRNAs (let-7b, miRNA-34a, -125b, -143, -145 and -221) was downregulated, and three microRNAs (miRNA-21, -25 and miRNA-93) were upregulated in tumour tissue compared to benign prostate tissue. In plasma, six microRNAs were upregulated (miRNA-21, -125b, -126, -141, -143 and -375), while let-7b was downregulated in patients with metastatic prostate cancer compared to the control cohort. In the metastatic prostate cancer cohort, the expression of four microRNAs (miRNA-125b, -126, -143 and -221), and miRNA-141 in tissue was associated with Gleason score and prostate-specific antigen, respectively. The expression of miRNA-93 in tumour tissue was correlated with matched plasma levels and showed a significant decrease in plasma level after intervention in local prostate cancer. Differential expression between tumour and benign prostate was detected for several microRNAs in both tissue and plasma.

Entities:  

Keywords:  Polymerase chain reaction; metastatic prostate cancer; microRNAs; plasma; tissue

Mesh:

Substances:

Year:  2018        PMID: 29775158     DOI: 10.1177/1010428318775864

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  18 in total

Review 1.  Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.

Authors:  Michela Bottani; Giuseppe Banfi; Giovanni Lombardi
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

2.  Expression of microRNAs in human platelet-poor plasma: analysis of the factors affecting their expression and association with proximal genetic variants.

Authors:  Alba Rodriguez-Rius; Angel Martinez-Perez; Sonia López; Maria Sabater-Lleal; Juan Carlos Souto; José Manuel Soria
Journal:  Epigenetics       Date:  2020-06-24       Impact factor: 4.528

3.  MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas.

Authors:  Samantha M Ruff; Reed I Ayabe; Parisa Malekzadeh; Meghan L Good; Michael M Wach; Melissa K Gonzales; Amit Tirosh; Naris Nilubol; Karel Pacak; Electron Kebebew; Dhaval Patel
Journal:  J Surg Res       Date:  2019-05-27       Impact factor: 2.192

4.  Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy.

Authors:  Ahmed H Zedan; Torben F Hansen; Jannie Assenholt; Jonna S Madsen; Palle J S Osther
Journal:  Prostate       Date:  2018-12-09       Impact factor: 4.104

5.  Up-regulation of miR-381 inhibits NAD+ salvage pathway and promotes apoptosis in breast cancer cells.

Authors:  Zahra Bolandghamat Pour; Mitra Nourbakhsh; Kazem Mousavizadeh; Zahra Madjd; Seyedeh Sara Ghorbanhosseini; Zohreh Abdolvahabi; Zahra Hesari; Samira Ezzati Mobaser
Journal:  EXCLI J       Date:  2019-08-27       Impact factor: 4.068

6.  Single-molecule amplification-free multiplexed detection of circulating microRNA cancer biomarkers from serum.

Authors:  Shenglin Cai; Thomas Pataillot-Meakin; Akifumi Shibakawa; Ren Ren; Charlotte L Bevan; Sylvain Ladame; Aleksandar P Ivanov; Joshua B Edel
Journal:  Nat Commun       Date:  2021-06-10       Impact factor: 14.919

Review 7.  Exosomes of pasteurized milk: potential pathogens of Western diseases.

Authors:  Bodo C Melnik; Gerd Schmitz
Journal:  J Transl Med       Date:  2019-01-03       Impact factor: 5.531

8.  Microarray profiling identifies extracellular circulating miRNAs dysregulated in cystic fibrosis.

Authors:  Justin E Ideozu; Xi Zhang; Vittobai Rangaraj; Susanna McColley; Hara Levy
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

9.  MiR-93/miR-375: Diagnostic Potential, Aggressiveness Correlation and Common Target Genes in Prostate Cancer.

Authors:  Ewa Ciszkowicz; Paweł Porzycki; Małgorzata Semik; Ewa Kaznowska; Mirosław Tyrka
Journal:  Int J Mol Sci       Date:  2020-08-07       Impact factor: 5.923

10.  Adipose tissue from metabolic syndrome mice induces an aberrant miRNA signature highly relevant in prostate cancer development.

Authors:  Cintia Massillo; Rocío Belén Duca; Ezequiel Lacunza; Guillermo Nicolás Dalton; Paula Lucía Farré; Nicolás Taha; Flavia Piccioni; Georgina Daniela Scalise; Kevin Gardner; Adriana De Siervi
Journal:  Mol Oncol       Date:  2020-09-25       Impact factor: 7.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.